Ali Alzahrani

Prof. Ali Alzahrani


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
AAAli Alzahrani
Ali Alzahrani

15 March 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
RTR Michael Tuttle
R Michael Tuttle
AAAli Alzahrani
Ali Alzahrani
Context: Modern management of differentiated thyroid cancer requires individualized care plans that tailor the intensity of therapy and follow-up to the estimated risks of recurrence and disease-specific mortality. Design: This summary is based on the authors’ knowledge and extensive clinical experience, supplemented by review of published review articles, thyroid cancer management guidelines, published staging systems, and original articles identified through a PubMed search, which included terms such as risk stratification, staging, clinical outcomes, and differentiated thyroid cancer. Main Outcome Measures: In the past, risk stratification in differentiated thyroid cancer usually referred to a static estimate of disease-specific mortality that was based on a small set of clinicopathological features available within a few weeks of completing initial therapy (thyroidectomy, with or without radioactive iodine). Today, risk stratification is a dynamic, active process used to predict the appropriateness for minimalistic initial therapy, disease-specific mortality, risk of recurrence, and the most likely response to initial therapy. Rather than being a static prediction available only after initial therapy, modern risk stratification is a dynamic, iterative process that begins as soon as a suspicious nodule is detected and continues through final follow-up. Conclusions: Dynamic risk assessment should be used to guide all aspects of thyroid cancer management, beginning before a definitive diagnosis is made and continuing through the final follow-up visit.

1 February 2021 in Endocrine Practice
Verified
Journal Article
Closed access
AAAli Alzahrani
Ali Alzahrani
NMNoha Mukhtar
Noha Mukhtar
AAAbeer Aljomaiah
Abeer Aljomaiah
HAHadeel Aljamei
Hadeel Aljamei
ABAbdulmohsen Bakhsh
Abdulmohsen Bakhsh
OSOthman Sulaiman
Othman Sulaiman

22 February 2016 in Discover Oncology
Verified
Journal Article
Closed access
PDF file
AAAli Alzahrani
Ali Alzahrani
RARawan Alsaadi
Rawan Alsaadi
AMAvaniyapuram Kannan Murugan
Avaniyapuram Kannan Murugan
BSBakr Bin Sadiq
Bakr Bin Sadiq

1 February 2017 in Thyroid®
Verified
Journal Article
Closed access
AAAli Alzahrani
Ali Alzahrani
AMAvaniyapuram Kannan Murugan
Avaniyapuram Kannan Murugan
EQEbtesam Qasem
Ebtesam Qasem
MAMeshael Alswailem
Meshael Alswailem
HAHindi Al-Hindi
Hindi Al-Hindi
YSYufei Shi
Yufei Shi
Purpose: Differentiated thyroid cancer (DTC) is rare in children. Previous studies have suggested that it has different clinicopathologic features and mutation profiles compared with adult DTC. However, those studies focused on a single or limited number of gene mutations. This study comprehensively investigated a large series of pediatric DTC for single point mutations in BRAF , HRAS , KRAS , NRAS , PIK3CA , PTEN , and TERT . It also analyzed associations between clinicopathologic features and the BRAF V600E mutation. Patients and Methods: Eighty-nine consecutive cases seen in children and adolescents (≤18 years) during 1998–2015 were identified. Rare variants of DTC were excluded, and the study focused on 72 (91.1%) classical papillary thyroid carcinoma (PTC) and seven (8.9%) follicular variant PTC. These included 68 (86.1%) females and 11 (13.9%) males, with a median age of 15.5 years (range 8–18 years). The clinical and histopathological data were obtained from medical records. DNA was extracted from paraffin-embedded tumor tissue, and was PCR-amplified and directly sequenced. Results: Mutations detected included BRAF V600E in 19/72 (26.4%) classical PTC samples, and in none of seven follicular variant PTC. Other mutations included: 1/78 (1.3%) successfully amplified tumor samples with TERT  C228T ; 2/79 (2.5%) NRAS 61 (c.181C>A and c.182A>G); 1/73 (1.4%) PIK3CA exon 9 (c.1589A>G and c.1598C>T in one tumor); 1/79 (1.3%) PIK3CA exon 20 (c.2951G>A); and 1/74 (1.4%) PTEN exon 5 (c.295G>A). No mutation was found in HRAS , KRAS , NRAS12 , PTEN exons 6, 7, and 8, and TERT  C250T . No significant association was found between BRAF V600E mutation and sex, extrathyroidal invasion, tumor multifocality, vascular invasion, lymph node or distant metastases, and persistent/recurrent disease. Conclusions: In pediatric DTC, the prevalence of the BRAF V600E mutation is significantly less common compared with adult DTC, and there is no association between this mutation and the histopathological features and outcome of PTC. PIK3CA , PTEN , NRAS 61, and TERT  C228T mutations are rare.

28 June 2015 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
AAAli Alzahrani
Ali Alzahrani
DADania Alkhafaji
Dania Alkhafaji
MTMahmoud Tuli
Mahmoud Tuli
HAHindi Al‐Hindi
Hindi Al‐Hindi
BSBakr Bin Sadiq
Bakr Bin Sadiq